Quantum Biopharma QNTM

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    +$0.09 (+0.40%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Quantum Biopharma (QNTM) Business Model and Operations Summary
    Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada.

    Key Insights

    Quantum Biopharma (QNTM) Core Market Data and Business Metrics

    • Latest Closing Price

      $22.35

    • Market Cap

      $78.88 Million

    • Average Daily Volume

      472,925 Shares

    • 52-Week Range

      $2.70-$38.25

    • Total Outstanding Shares

      3.04 Million Shares

    • CEO

      Mr. Zeeshan Saeed

    • Total Employees

      7

    • Current Dividend

      No dividend

    • IPO Date

      June 7, 2018

    Earnings Reports

    Expected vs. Actual Quarterly Earnings-Per-Share & Revenue

    Short Volume

    Daily short volume activity identifies short-term trading pressure and potential price volatility

    Short Interest

    Bi-monthly short interest levels can be used to gauge bearish market sentiment and short squeeze potential

    Revenue Breakdown

    Distribution of revenue across unique business segments & geographies

    Historical Stock Splits

    If you bought 1 share of QNTM before August 15, 2024, you'd have 20 shares today

    Historical Dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about QNTM from trusted financial sources

    Related Companies

    Publicly traded companies similar to Quantum Biopharma (QNTM)
    Boost your savings and earn 3.95% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.

    Play

    The Daily FinanchleSPY Prediction

    Explore

    Live Market OverviewS&P 500 SPYNasdaq 100 QQQRussell 2000 IWMUnusual Options Activity

    Research

    News ArticlesEarnings CalendarIPO Calendar & DirectoryAll Tickers

    Financhle

    Login / Sign UpPro SubscriptionAbout UsTerms & ConditionsPrivacy & Cookies Info

    ⓒ 2025 Financhle. All Rights Reserved.